SPL
Click for more information
2.11% 9.3¢ starpharma holdings limited

Ann: VIRALEZE antiviral nasal spray registered in Europe, page-2

  1. col69
    15,510 Posts.
    lightbulb Created with Sketch. 5586
    clock Created with Sketch.
    23/02/21
    09:24
    Post #: 51235598
    Ouch to the remaining shorts as it includes the UK  ... LMAO

    Melbourne, Australia; 23 February 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) announced today it had received confirmation that the VIRALEZE™ antiviral nasal spray has been successfully registered for sale in Europe, including in the UK.
    SPL Price at posting: $2.20 Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 16  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

WCN White Cliff wraps up Canadian fieldwork programs – 'visually confirming' a slew of minerals
right-arrow Created with Sketch.
LML Lincoln repositions Kookaburra for low-cost graphite delivery
right-arrow Created with Sketch.
STX Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
right-arrow Created with Sketch.
KAI Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
right-arrow Created with Sketch.
GML Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
right-arrow Created with Sketch.
CKA Deal with Petrosea opens the door for Cokal's ramp-up plans in Indonesia
right-arrow Created with Sketch.
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.3¢ 		Change
-0.002(2.11%) 		Mkt cap ! $38.35M
Open High Low Value Volume
9.5¢ 9.5¢ 9.3¢ $48.64K 512.2K

Buyers (Bids)

No. Vol. Price($)
3 153365 9.3¢
 

Sellers (Offers)

Price($) Vol. No.
9.8¢ 65000 1
View Market Depth
Last trade - 16.10pm 02/08/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.